Provided is a solid catalyst component for olefin polymerization, which comprises Mg, Ti, a halogen and an electron donor. The electron donor is selected from at least one of ring-substituted ether-acid ester compounds of the general formula (I). Also provided are a catalyst containing the solid catalyst component and the application of the catalyst in reactions of olefin polymerization, particularly in the reaction of propylene polymerization.

A problem is to provide a liquid crystal compound satisfying at least one physical property such as high stability to heat and light, a high clearing point (or high maximum temperature), a low minimum temperature of a liquid crystal phase, small viscosity, suitable optical anisotropy, large dielectric anisotropy, a suitable elastic constant and excellent compatibility with other liquid crystal compounds, a liquid crystal composition containing the compound and a liquid crystal display device including the composition. A solution is a compound represented by formula (1). ##STR00001## In which, R.sup.1 is alkyl having 1 to 10 carbons or the like; Z.sup.1, Z.sup.2 and Z.sup.3 are independently a single bond, —COO—, —OCH.sub.2—, —CF.sub.2O— or the like, and at least one of Z.sup.1, Z.sup.2 and Z.sup.3 is —CF.sub.2O—; X.sup.1 is hydrogen, fluorine, —CF.sub.3 or —OCF.sub.3; and L.sup.1, L.sup.2, L.sup.3 and L.sup.4 are independently hydrogen, fluorine or chlorine.

A problem is to provide a liquid crystal compound satisfying at least one physical property such as high stability to heat and light, a high clearing point (or high maximum temperature), a low minimum temperature of a liquid crystal phase, small viscosity, suitable optical anisotropy, large dielectric anisotropy, a suitable elastic constant and excellent compatibility with other liquid crystal compounds, a liquid crystal composition containing the compound and a liquid crystal display device including the composition. A solution is a compound represented by formula (1). ##STR00001## In which, R.sup.1 is alkyl having 1 to 10 carbons or the like; Z.sup.1, Z.sup.2 and Z.sup.3 are independently a single bond, —COO—, —OCH.sub.2—, —CF.sub.2O— or the like, and at least one of Z.sup.1, Z.sup.2 and Z.sup.3 is —CF.sub.2O—; X.sup.1 is hydrogen, fluorine, —CF.sub.3 or —OCF.sub.3; and L.sup.1, L.sup.2, L.sup.3 and L.sup.4 are independently hydrogen, fluorine or chlorine.

The present invention provides a catalyst composition exhibiting, by including a lanthanide rare earth element-containing compound; modified methylaluminoxane; a halogen compound; and an aliphatic hydrocarbon-based solvent, excellent catalytic activity even with a small main catalyst amount, capable of preparing a conjugated diene-based polymer having excellent catalytic activity and thereby having high cis-1,4-bond content ratio, high linearity, and narrow molecular weight distribution, and capable of reducing polymerization reaction time, and a method for preparing the same.

The present invention provides a catalyst composition exhibiting, by including a lanthanide rare earth element-containing compound; modified methylaluminoxane; a halogen compound; and an aliphatic hydrocarbon-based solvent, excellent catalytic activity even with a small main catalyst amount, capable of preparing a conjugated diene-based polymer having excellent catalytic activity and thereby having high cis-1,4-bond content ratio, high linearity, and narrow molecular weight distribution, and capable of reducing polymerization reaction time, and a method for preparing the same.

The present invention relates to novel cannabigerol quinone derivatives of formula (I) wherein R is the carbon atom of a linear or branched group, represented by: aryl, alkenyl, alkynyl or alcoxycarbonil groups; or wherein R is the nitrogen atom of a linear or branched group, represented by: alkylamino, arylamino, alkenylamino or alkynylamino groups; or, alternatively, R represents a bond between 2 molecules of formula (I) forming a dimer. The invention also relates to the use of any of the compounds of formula (I) as medicaments in therapy, particularly for treating PPARg-related diseases due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.

##STR00001##

The present invention relates to novel cannabigerol quinone derivatives of formula (I) wherein R is the carbon atom of a linear or branched group, represented by: aryl, alkenyl, alkynyl or alcoxycarbonil groups; or wherein R is the nitrogen atom of a linear or branched group, represented by: alkylamino, arylamino, alkenylamino or alkynylamino groups; or, alternatively, R represents a bond between 2 molecules of formula (I) forming a dimer. The invention also relates to the use of any of the compounds of formula (I) as medicaments in therapy, particularly for treating PPARg-related diseases due to their high PPARg agonistic effect lacking electrophilic (Nrf2 activation) and cytotoxic activities. This invention also provides pharmaceutical compositions comprising said compounds and method of treating diseases with said compounds.

##STR00001##

This invention relates to methods for the synthesis of spiro[2.5]octane-5, 7-dione and spiro[3.5]nonane-6, 8-dione which are useful as intermediates in the manufacture of pharmaceutically active ingredients.

This invention relates to methods for the synthesis of spiro[2.5]octane-5, 7-dione and spiro[3.5]nonane-6, 8-dione which are useful as intermediates in the manufacture of pharmaceutically active ingredients.

This invention relates to methods for the synthesis of spiro[2.5]octane-5, 7-dione and spiro[3.5]nonane-6, 8-dione which are useful as intermediates in the manufacture of pharmaceutically active ingredients.